Actively Recruiting

Age: 18Years +
All Genders
NCT06905106

POlycythemia, Proteins and ErYthropoiesis

Led by Centre Hospitalier Universitaire Dijon · Updated on 2025-04-01

400

Participants Needed

1

Research Sites

208 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Erythropoiesis encompasses all the stages and mechanisms involved in the production of red blood cells, or erythrocytes, under the control of a large number of regulatory agents, most often proteins. Among these proteins, erythropoietin and interleukin-3 play a major role. Similarly, proteins involved in iron metabolism (erythroferrone, hepcidin, ferroportin, transferrin, ferritin) influence erythrocyte production more or less directly. The regulation of erythropoiesis is a fine, complex mechanism involving a large number of players, not only through the stimulation of hypoxia pathways to control erythropoietin synthesis, but also through the availability of iron, an essential element for erythropoiesis. Excessive erythrocyte production can lead to polycythemia, the causes of which are varied, primary or secondary, acquired or constitutional. The aim of this work is the descriptive study (quantitative and/or qualitative) of the various proteins involved in the regulation of erythropoiesis in patients with polycythemia. These proteins will be measured in the plasma of patients obtained after blood sampling or bloodletting (bloodletting being the most common treatment for polyglobulic patients) and will be compared with the proteins of patients without polycythemia.

CONDITIONS

Official Title

POlycythemia, Proteins and ErYthropoiesis

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Persons who have given their non-opposition
  • Patients with polycythemia having hemoglobin value > 16 g/dl for females or > 16.5 g/dl for males
  • Patients with a well-identified cause of polycythemia, either primary (such as polycythemia Vaquez, erythropoietin receptor or LNK/SH2B3 mutation) or secondary (including cardio-respiratory pathologies, renal pathologies like post-transplant or polycystic kidney disease, metabolic pathologies, tumors like leiomyoma or pheochromocytoma, and constitutional mutations such as hyperaffine hemoglobins, HIF2/EPAS1, PHD/EGLN1, VHL)
  • Control patients with similar pathologies to polycythemia patients but without polycythemia, having hemoglobin value < 16 g/dl for females and < 16.5 g/dl for males
Not Eligible

You will not qualify if you...

  • Persons subject to a measure of legal protection (guardianship, tutorship)
  • Persons subject to a court order
  • Pregnant, parturient or nursing women
  • Persons incapable of expressing consent
  • Minors

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

CHU Dijon Bourgogne

Dijon, France, 21000

Actively Recruiting

Loading map...

Research Team

F

François GIRODON

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here